Vitiligo Research Reagents

Vitiligo is an autoimmune disease of the skin affecting ~1% of the global population, characterized by progressive destruction of melanocytes resulting in patches of depigmentation. The central pathogenic mechanism is the IFN-γ–CXCL10–CXCR3 positive-feedback axis: autoreactive CD8+ T cells produce IFN-γ in the skin, which induces keratinocytes to secrete CXCL10 (IP-10), further recruiting CXCR3+ cytotoxic T cells to the epidermis for melanocyte killing via granzyme B/perforin pathways. Tissue-resident memory T cells (TRM) maintain depigmented lesions even after active inflammation subsides. Ruxolitinib cream (JAK1/2 inhibitor) is the first FDA-approved therapy for nonsegmental vitiligo, validating the JAK-STAT/IFN-γ signaling pathway as a therapeutic target. Emerging approaches include anti-CXCL10, anti-IL-15 (targeting TRM maintenance), and combination strategies with phototherapy.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Vitiligo Research Reagents — key pathogenic pathways including IFN-gamma/CXCL10/CXCR3 axis, CD8+ T cell-mediated melanocyte destruction, JAK-STAT signaling, and granzyme B/perforin cytotoxicity

Fig. 1 Key pathogenic pathways in vitiligo. IFN-γ drives CXCL10 production from keratinocytes; CXCL10/CXCR3 axis recruits CD8+ T cells; granzyme B/perforin mediates melanocyte killing; JAK1/2 inhibition (ruxolitinib) blocks the IFN-γ signaling loop. Key research targets highlighted in orange.

abinScience provides validated anti-CXCL10 reference antibodies, anti-CXCR3 recombinant antibodies (4 clones with fluorescent conjugates), anti-IFN-γ antibodies and proteins, and granzyme B/perforin antibodies for vitiligo immunopathology research. Melanocyte biology reagents (anti-tyrosinase, anti-SOX10) are also available. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

CXCL10 (IP-10) / CXCR3 — The CXCL10/CXCR3 chemokine axis is the central T cell recruitment pathway in vitiligo. IFN-γ-induced CXCL10 from keratinocytes recruits CXCR3+ CD8+ T cells to the epidermis, creating a positive-feedback loop that sustains melanocyte destruction. Serum CXCL10 is the leading disease activity biomarker. abinScience offers anti-CXCL10 reference antibodies (Eldelumab, NI-0801), anti-CXCL10 recombinant antibodies (human SAA0413, mouse SAA0412), and anti-CXCR3/CD183 recombinant antibodies (4 clones: V3G6, 5H7, 1C6, 7H5) with fluorescent conjugates for flow cytometric T cell phenotyping and chemotaxis assays.
→ Browse CXCL10 & CXCR3 antibodies

IFN-γ / JAK-STAT — IFN-γ is the master cytokine driving vitiligo pathogenesis, inducing CXCL10 production, upregulating melanocyte MHC-I expression, and promoting cytotoxic T cell activation. Ruxolitinib (JAK1/2 inhibitor) blocks downstream IFN-γ signaling via the JAK-STAT1 pathway. Anti-IFN-γ reference antibodies, recombinant antibodies with fluorescent conjugates, recombinant IFN-γ proteins, and anti-JAK1/JAK2 polyclonal antibodies with recombinant proteins support cytokine profiling, JAK-STAT signaling pathway dissection, and ruxolitinib mechanism-of-action studies.
→ Browse IFN-γ & JAK antibodies

Granzyme B / Perforin — CD8+ cytotoxic T cells kill melanocytes via the granzyme B/perforin pathway. Granzyme B cleaves intracellular substrates to trigger apoptosis, while perforin forms pores in the target cell membrane for granzyme B delivery. Anti-granzyme B recombinant antibodies (clones Fv02, scFv17) and anti-perforin recombinant antibody (clone SAA0104) are available with fluorescent conjugates (FITC, PE, APC, PerCP) for perilesional T cell cytotoxicity profiling by flow cytometry and IHC on skin biopsies.
→ Browse granzyme B & perforin antibodies

Melanocyte Biology (Tyrosinase / SOX10) — Tyrosinase (TYR) is the rate-limiting enzyme in melanin biosynthesis and a melanocyte-specific autoantigen. SOX10 is a transcription factor essential for melanocyte lineage specification and survival. Anti-tyrosinase recombinant antibody (clone SAA1969), anti-TYRP1 reference antibody (Flanvotumab) and recombinant antibody (clone TA99), and anti-SOX10 polyclonal antibody support melanocyte quantification in skin biopsies (IHC), melanocyte differentiation research, and autoantigen characterization in vitiligo.
→ Browse melanocyte biology antibodies

References

1. Frisoli ML, et al. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621-648. DOI

2. Rosmarin D, et al. Ruxolitinib cream for treatment of vitiligo. N Engl J Med. 2022;387(16):1445-1455. DOI